Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 1, 2015, Pages e10-e12

  Surgers, Laure ^a   Valin, Nadia ^b   Viala, Céline ^c   Boyd, Anders ^d   Fonquernie, Laurent ^a   Girard, Pierre Marie ^b   Morand Joubert, Laurence ^c   Meynard, Jean Luc ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PROTON PUMP INHIBITOR; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; NITRILE; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE; RILPIVIRINE; TENOFOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTHRALGIA; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; LETTER; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SLEEP DISORDER; VIRUS LOAD; ANALOGS AND DERIVATIVES; DRUG COMBINATION; HIV INFECTIONS; MIDDLE AGED; YOUNG ADULT;

ADENINE; ADULT; AGED; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NITRILES; ORGANOPHOSPHONATES; PYRIMIDINES; YOUNG ADULT;

EID: 84919360209     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000401     Document Type: Letter

References (8)

1. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-246
2. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378:229-237
3. Palella FJ Jr, Fisherb M, Tebasc P, et al. Simplification to rilpivirine/emtricitabine/tenofovirdisoproxilfumaratefrom ritonavirboosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014; 28:335-344
4. Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovirdisoproxilfumarate-based single-tablet regimens. HIV Clin Trials. 2013; 14:216-223
5. Maggiolo F, Callegaro A, Cologni G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012;60: 473-482
6. Rokx C, Verbon A, Rijnders BJA. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy. HIV Med. 2014;15: 611-614
7. Eron J, Young B, Cooper D, et al; SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375: 396-407
8. Lambert-Niclot S, Flandre P, Valantin MA, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis. 2011;204:1211-1216.